Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 9/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241180 | 0.82 | HCRTR2 (0.37) | HCRTR2HCRTR1NPSR1CA12CA9 | |
| SCHEMBL9950175 | 0.81 | HCRTR2 (0.59) | HCRTR2HCRTR1CYP2C8CYP2C19 | |
| SCHEMBL9951521 | 0.80 | HCRTR2 (0.40) | HCRTR2HCRTR1POLBHTT | |
| SCHEMBL9950268 | 0.80 | HCRTR2 (0.40) | HCRTR2HCRTR1CYP2C8CYP2C19CYP3A4 | |
| SCHEMBL9950639 | 0.80 | HCRTR2 (0.44) | HCRTR2HCRTR1NPSR1CA12CA9 | |
| SCHEMBL9950858 | 0.76 | CA12 (0.41) | HCRTR2HCRTR1NPSR1CA12CA9 | |
| SCHEMBL9950738 | 0.74 | CYP3A4 (0.39) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL9951170 | 0.74 | CYP3A4 (0.39) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL9950322 | 0.74 | OPRK1 (0.43) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2117864 | 0.74 | OPRK1 (0.43) | CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR2 1/4885HCRTR1 2/4885NPSR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.